Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda

Domain:

healthcare

Creator:

SteCisFraRob

Publisher:

SAG

Host:

Background This study aimed to determine the extent of viral resistance over time among non-clade B HIV type-1-infected patients in Uganda who were maintained on first-line highly active antiretroviral therapy (HAART) following virological failure. Methods Genotyping was performed on 16 patients with virological failure who were enrolled in an open-label randomized clinical trial of short-cycle treatment interruption. Results All patients receiving efavirenz-containing HAART had ≥1 efavirenz resistance mutation develop during follow-up. The majority (13/15, 86%) developed lamivudine resistance during follow-up, but no thymidine analogue mutations (TAMs) developed during a median duration of virological failure of 325.5 days. Conclusions Genotype resistance to both efavirenz and lamivudine developed early during the course of treatment after virological failure. TAMs did not emerge early despite moderate exposure time to thymidine analogues during virological failure.

Visit

doi.org

Licenses

https://journals.sagepub.com/page/policies/text-and-data-mining-license

Evolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, Zambia

Background HIV viral load (VL) and resistance testing are limited in sub-Sahar

Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa

Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe

Objective: Dolutegravir (DTG)-based antiretroviral therapy (ART) is being scaled up in

Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation

International audience Background: We described reasons for switching to second-line

Drug Resistance After Failure of WHO Recommended First-Line Antiretroviral Regimen for Adult HIV-1 Infection in South Africa: A Modeling Analysis

Abstract Background Antiretroviral therapy

Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda

Abstract Objectives We implemented the WHO cross-sectional survey protocol to determine rates of